Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-ALBA: Dasatinib and Blinatumomab in Ph+ ALL
NCT02744768Phase 2Unknown
- Sponsor
- GIMEMA
- Start
- May 2017
- Primary completion
- Jun 2021
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, scFv Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Status: unknown.
02
Drugs
dasatinibblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02744768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02744768.